Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.

"Competing interests The authors declare no competing interests."

"Funding ASC received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No # 860245 (to MV). E.H. was supported by an aspirant FWO fellowship 1106119N. KRK received funding to perform metabolomics mass spectrometry analysis, which was funded by a research grant from FWO (FWO KAN2018 871 1501419N), further experiments were supported by the KNAW early career award 2022 and FEBS excellence award 2022 (to KRK)."

"Patients diagnosed with stage I or stage III NSCLC scheduled for curative-intent RT and chemoradiation (CCRT), respectively, were prospectively included at MAASTRO (Maastricht, The Netherlands) and University Hospitals Leuven (UZ Leuven, Leuven, Belgium) between May 2017 and March 2019. This study was approved by the ethics committees of UZ/ KU Leuven and MUMC (NL59321.068.16/ METC 163073). Patient samples were obtained after a signed informed consent in agreement with Helsinki’s declaration. This study was registered in ClinicalTrials.gov Identifier: (NCT02921854) []."